Women Still Underrepresented on Structural Heart Disease Trial Committees

Deliberate efforts are needed to change the situation, which hasn’t improved much since 2010, researchers say.

Women Still Underrepresented on Structural Heart Disease Trial Committees

Most high-impact trials of structural heart disease interventions published since 2010 did not have a single woman on their steering/executive committees, a systematic review and meta-analysis shows.

Of the randomized controlled trials or single-arm investigational device exemption trials with information available, 56.2% had oversight committees that were made up entirely of men, with only 7.0% of committee seats overall going to women, lead author Sahar Samimi, MD (Baylor College of Medicine, Houston, TX), and colleagues report.

Moreover, women chaired only 12.0% of trial committees and served as senior author (first or last position) on just 14.0% of publications.

These proportions remained relatively stable, with no significant gains observed over time.

Over the last 10 to 15 years, there have been dramatic advancements in technologies and procedures used to treat structural heart disease, with guideline-changing results. Yet that has not been accompanied by an increase in the number of women in trial leadership positions, senior author Mayra Guerrero, MD (Mayo Clinic, Rochester, MN), told TCTMD.

“It’s not very surprising, but to be honest, I was hoping to see better results and progress over time,” she said.

“We’ve been talking about this for years and in my 20-plus-year career, I have seen so much progress in technology, so much progress in the field,” Guerrero added. “But the one thing that has not evolved at the same speed is women representation in the field in general, with significant consequences for representation in clinical trials, unfortunately.”

Neither did the findings, published online recently in JACC: Advances, come as a surprise to Harriette Van Spall, MD (Population Health Research Institute, McMaster University, Hamilton, Canada), who has researched gender equity in cardiovascular clinical trials.

The analysis “confirms what we already know—that women are less frequently the individuals who are represented in steering committees for our cardiovascular clinical trials, and that the general temporal trends haven’t really changed,” she commented to TCTMD. “The proportion of women across subspecialty trials tends to vary according to the proportion in subspecialties [themselves]. However, I would say that relative to the clinical representation, there’s still an underrepresentation in clinical trial committees.”

There are many reasons for that, Van Spall said, adding that “given how much there has been published in this area for decades now, I think the needle needs to shift more towards resolving the issue and thinking about actionable solutions at different levels.”

No Major Improvement Over Time

Prior studies have shown that women are much less likely to lead cardiovascular clinical trials than men, but that when they do assume leadership positions, it’s associated with increased enrollment of female participants. The issue has gained a lot of attention over the past several years, with a group led by Van Spall issuing, in 2021, a road map to address the underrepresentation of women in trial leadership.

The current systematic review and meta-analysis focused specifically on women representation on the oversight committees of high-impact interventional structural heart disease trials published between 2010 and 2025. There were 88 total trials, including 57 involving aortic valve disease, 12 mitral valve disease, seven left atrial appendage occlusion (LAAO), seven patent foramen ovale (PFO) closure, and five tricuspid valve disease. About two-thirds of trials (67.8%) reported an oversight committee, and 55.8% provided the names of committee members.

Of the 512 total committee seats with names attached, women held only 36. The proportion of seats held by women was lowest for trials in the aortic space (4.9%) and highest for those assessing treatments for mitral disease (14.5%).

There were no major changes over time in the proportion of women who served in any capacity on an oversight committee (OR per year 1.02; 95% CI 0.93-1.12) or in the likelihood of women serving as chair (OR per year 1.41; 95% CI 1.05-2.34; P = 0.075).

The lingering underrepresentation of women in trial leadership may influence how evidence is generated from these studies, Samimi et al suggest. “Clinical trial leadership influences which research questions are prioritized, which patient populations are included, how endpoints are selected, and how results are interpreted and disseminated,” they write. “As such, disparities in leadership may contribute to inequities in the evidence base that informs clinical practice.”

Causes and Solutions

One factor contributing to the low number of women on steering/executive committees is the small proportion of female operators who perform these procedures, Guerrero indicated, noting that prior research has shown that only 3.1% of physicians who do TAVI are women.

“We need to have more women in the interventional cardiology field to begin with, [which will lead to] more women who actually have the opportunity to do these procedures as operators and then participate in these trials,” she said. “It would be very difficult to be leading one of these trials as a woman and not be the one who is involved in these procedures.”

Guerrero pointed out that over the past 3 to 5 years at her center, more women have been accepted into interventional fellowships and have completed additional training in structural interventions, mirroring trends around the country. “It is going to take time, but maybe in the next 5 to 10 years, we may see a proportional increase in representation of women in clinical trials,” she said. “That would be my hope.”

But Van Spall said a growing number of women entering training and practice will not be enough to overcome the underrepresentation of female researchers, noting that principal investigators don’t always receive salary support and dedicated time to lead trials.

“While the clinical space will change as more women enter the field, I think there have to be proactive steps towards ensuring that women who are trained in research, who have the fire to lead research, and who verbalize and demonstrate strides in being successful at research are rewarded with protected time and some salary support,” she commented.

We do have the ability and the skills and the capacity to change some of these static trends by focusing on ground-up efforts—what is within our sphere of control. Harriette Van Spall

Guerrero agreed that more deliberate measures are needed, pointing to deliberate efforts that can be made at the level of institutions, industry sponsors, and perhaps the US Food and Drug Administration to get more women on leadership committees, including invitations to apply for open seats.

Van Spall said that industry, in particular, has made efforts to be more inclusive when forming trial leadership committees.

“I lead a couple of trials as international PI that are industry-sponsored, and I see industry partners making large efforts to offer equal opportunity,” she said. “But yet there are imbalances still on the ground, and these come at the institution level where there are informal networks that mentor people and where women sometimes get left behind.”

Women who are already in leadership positions can help get more women involved in running trials, both Guerrero and Van Spall said.

Female leaders “need to provide or create more opportunities for other talented women that may be interested in the field but have not received an opportunity,” Guerrero said.

Van Spall said that in her career, she completed research-specific training and took steps to design and execute her own investigator-initiated trials, allowing her to shape steering committees. “Steering committee roles provide a fantastic opportunity to lean in and really demonstrate expertise and collaboration and the ability to work well and understand all aspects of trial execution, [something that’s necessary] in order for that opportunity to grow into a leadership role beyond a steering committee role,” she said.

Van Spall stressed that “we do have the ability and the skills and the capacity to change some of these static trends by focusing on ground-up efforts—what is within our sphere of control—by writing protocols, obtaining peer-reviewed funding, building research networks, and inviting others to join some of the trials that we lead. And that could be a step towards changing the trend that’s described in this article.”

In an accompanying editorial, Roxana Mehran, MD (Icahn School of Medicine at Mount Sinai, New York, NY), president of the American College of Cardiology, and colleagues lay out a framework for achieving equity in trial leadership. They point to the need for transparency when it comes to reporting the composition of steering committees in all major trial publications; expansion of early pathways to leadership roles; re-examination of how leadership roles have traditionally been allocated; and accountability across multiple stakeholders that includes clear benchmarks and regular assessments of whether they’re being met.

“Achieving equity in trial leadership is not simply a matter of fairness. It is essential to advancing the field and ensuring that innovation is inclusive, representative, and broadly applicable,” Mehran et al write. “The challenge is no longer to define the problem or propose solutions—it is to implement them.”

Sources
Disclosures
  • Guerrero reports having received institutional research grant support from Edwards Lifesciences.
  • Samimi reports no relevant conflicts of interest.
  • Mehran reports having received institutional research grants from Abbott, Abiomed, Applied Therapeutics, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis, and OrbusNeich; consultant fees from Abbott, Boston Scientific, Janssen Scientific Affairs, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences, Sanofi, and Siemens Medical Solutions; consultant fees paid to the institution from Abbott and Bristol Myers Squibb; advisory board, funding paid to the institution from Spectranetics/Philips/Volcano Corp; and equity < 1% from Claret Medical and Elixir Medical. She also reports receiving DSMB membership fees paid to the institution from Watermark Research Partners; consulting (with no fee) for Idorsia and Regeneron; being associate editor for the American College of Cardiology and the American Medical Association; and having a spouse who consults for Abiomed, The Medicines Company, and Merck.

Comments